C12N2310/315 - page 10 - CPC Classification Index

#2701

20160333341

2016-11-17

MicroRNA compounds and methods for modulating miR-21 activity

#2702

20160331836

2016-11-17

Chiral nucleic acid adjuvant having antitumor effect and antitumor agent

#2703

20160331835

2016-11-17

Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent

#2704

20160326527

2016-11-10

Compositions and methods for treatment of prostate and other cancers

#2705

20160326526

2016-11-10

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

#2706

20160319283

2016-11-03

Methods for treatment of alport syndrome

#2707

20160319278

2016-11-03

FULLY STABILIZED ASYMMETRIC SIRNA

#2708

20160317671

2016-11-03

Cell penetrating conjugates and methods of use thereof

#2709

20160312217

2016-10-27

Modulation of huntingtin expression

#2710

20160311845

2016-10-27

Nucleotide derivative or salt thereof, nucleotide-derived 5′-phosphate ester or salt thereof, nucleotide-derived 3′-phosphoramidite compound or salt thereof, and polynucleotide

#2711

20160304880

2016-10-20

SiRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene

#2712

20160304877

2016-10-20

COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION

#2713

20160304876

2016-10-20

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#2714

20160304875

2016-10-20

METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES

#2715

20160304871

2016-10-20

Compositions for modulating C9ORF72 expression

#2716

20160304870

2016-10-20

Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA

#2717

20160304868

2016-10-20

Compositions of asymmetric interfering RNA and uses thereof

#2718

20160304864

2016-10-20

MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS

#2719

20160298124

2016-10-13

Complement component iRNA compositions and methods of use thereof

#2720

20160298123

2016-10-13

RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

#2721

20160298121

2016-10-13

Targeted augmentation of nuclear gene output

#2722

20160298118

2016-10-13

Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions

#2723

20160289759

2016-10-06

Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1

#2724

20160289677

2016-10-06

APOB Antisense Conjugate Compounds

#2725

20160289675

2016-10-06

Guide RNA with chemical modifications

#2726

20160281091

2016-09-29

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA

#2727

20160281089

2016-09-29

PREVENTION OF VIRAL INFECTIVITY

#2728

20160281087

2016-09-29

Modulation of T cell signaling threshold and T cell sensitivity to antigens

#2729

20160273037

2016-09-22

Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3

#2730

20160272979

2016-09-22

Organic compositions to treat beta-ENaC-related diseases

#2731

20160272978

2016-09-22

Compositions and methods for inhibiting gene expression of factor XII

#2732

20160272974

2016-09-22

Compositions and methods for inhibiting JC virus (JCV)

#2733

20160272971

2016-09-22

Disulfide-containing alkyne linking agents

#2734

20160272968

2016-09-22

Targeting microRNA-26a/b for the treatment of neurodegenerative disease

#2735

20160264972

2016-09-15

Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus

#2736

20160264968

2016-09-15

MODIFIED iRNA AGENTS

#2737

20160264967

2016-09-15

OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD

#2738

20160264966

2016-09-15

Compositions and methods for inhibiting expression of the LECT2 gene

#2739

20160264964

2016-09-15

RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

#2740

20160264963

2016-09-15

Compositions and Methods for Inhibiting Expression of Transthyretin

#2741

20160263253

2016-09-15

Suicide contrast agents targeting HIV reservoirs for theranostic eradication

#2742

20160257962

2016-09-08

RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION

#2743

20160257954

2016-09-08

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#2744

20160251658

2016-09-01

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

#2745

20160251657

2016-09-01

MicroRNA compounds and methods for modulating miR-122

#2746

20160251656

2016-09-01

MicroRNAs modulating the effect of glucocorticoid signaling

#2747

20160251655

2016-09-01

Compositions for modulating C9ORF72 expression

#2748

20160244768

2016-08-25

Method for reducing circulating leukocytes in a human subject

#2749

20160244767

2016-08-25

Antisense compounds targeting genes associated with cystic fibrosis

#2750

20160244766

2016-08-25

Compositions and methods for inhibiting expression of the ALAS1 gene

#2751

20160244765

2016-08-25

Reduced size self-delivering RNAI compounds

#2752

20160244763

2016-08-25

Complement component C5 iRNA compositions and methods of use thereof

#2753

20160244762

2016-08-25

Reducing intron retention

#2754

20160244760

2016-08-25

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

#2755

20160244757

2016-08-25

Compositions and methods for modulating neuronal excitability and motor behavior

#2756

20160244753

2016-08-25

MicroRNA compounds and methods for modulating miR-21 activity

#2757

20160237439

2016-08-18

Modular RNA regulators and methods

#2758

20160237434

2016-08-18

Modulation of apolipoprotein C-III expression

#2759

20160237432

2016-08-18

METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#2760

20160237427

2016-08-18

Tau antisense oligomers and uses thereof

#2761

20160230174

2016-08-11

TOLEROGENIC DENDRITIC CELLS TO TREAT INFLAMMATORY BOWEL DISEASE

#2762

20160230172

2016-08-11

COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#2763

20160222389

2016-08-04

MODULATORS OF COMPLEMENT FACTOR B

#2764

20160222383

2016-08-04

Antisense compositions and methods of making and using same

#2765

20160215292

2016-07-28

Notch 1 specific siRNA molecule

#2766

20160215291

2016-07-28

Nucleic acids and methods for the treatment of Pompe disease

#2767

20160208264

2016-07-21

Antisense-induced exon2 inclusion in acid alpha-glucosidase

#2768

20160208260

2016-07-21

Complex containing oligonucleotide having immunopotentiating activity and use thereof

#2769

20160208259

2016-07-21

Targeting microRNAs for metabolic disorders

#2770

20160208258

2016-07-21

miR-92 inhibitors and uses thereof

#2771

20160194645

2016-07-07

Compositions and methods for inhibiting expression of mutant EGFR gene

#2772

20160194642

2016-07-07

SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS

#2773

20160194638

2016-07-07

Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals

#2774

20160194637

2016-07-07

Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals

#2775

20160194636

2016-07-07

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

#2776

20160194349

2016-07-07

Compositions and methods for modulating angiopoietin-like 3 expression

#2777

20160186185

2016-06-30

Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

#2778

20160186180

2016-06-30

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#2779

20160186179

2016-06-30

Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro

#2780

20160186174

2016-06-30

SUBSTITUTED MORPHOLINO COMPOUNDS ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

#2781

20160186173

2016-06-30

C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders

#2782

20160186172

2016-06-30

Compositions and methods for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

#2783

20160177313

2016-06-23

Compositions and methods for increasing erythropoietin (EPO) production

#2784

20160177307

2016-06-23

PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders

#2785

20160177306

2016-06-23

Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field

#2786

20160177304

2016-06-23

CRISPR-based compositions and methods of use

#2787

20160177302

2016-06-23

MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes

#2788

20160168570

2016-06-16

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

#2789

20160168568

2016-06-16

Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)

#2790

20160160217

2016-06-09

COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING MUSCULAR DYSTROPHY

#2791

20160152983

2016-06-02

RIG-I ligands and methods for producing them

#2792

20160152974

2016-06-02

Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile

#2793

20160145629

2016-05-26

TMPRSS6 iRNA compositions and methods of use thereof

#2794

20160145626

2016-05-26

Compositions and methods for inhibiting expression of TMPRSS6 gene

#2795

20160145625

2016-05-26

Dnazyme for silencing the expression of EGFR

#2796

20160145622

2016-05-26

Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure

#2797

20160145620

2016-05-26

Oligomers with improved off-target profile

#2798

20160145617

2016-05-26

Compositions for modulating Tau expression

#2799

20160145614

2016-05-26

Double-stranded agents for delivering therapeutic oligonucleotides

#2800

20160145609

2016-05-26

Micro-RNA family that modulates fibrosis and uses thereof

#2801

20160145608

2016-05-26

Micro-RNA family that modulates fibrosis and uses thereof

#2802

20160145607

2016-05-26

Micro-RNA family that modulates fibrosis and uses thereof

#2803

20160138029

2016-05-19

Antisense-oligonucleotides as inhibitors of TGF-R signaling

#2804

20160138023

2016-05-19

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

#2805

20160138014

2016-05-19

ANTISENSE COMPOUNDS AND USES THEREOF

#2806

20160136195

2016-05-19

Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells

#2807

20160130586

2016-05-12

Preventive or therapeutic agent for fibrosis

#2808

20160130584

2016-05-12

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

#2809

20160130583

2016-05-12

Double-stranded antisense nucleic acid with exon-skipping effect

#2810

20160130582

2016-05-12

OLIGONUCLEOTIDE MODULATORS OF B-CELL CLL/LYMPHOMA 11A (BCL11A) AND USES THEREOF

#2811

20160130578

2016-05-12

Reduced size self-delivering RNAi compounds

#2812

20160122761

2016-05-05

COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS

#2813

20160122760

2016-05-05

COMPOSITIONS AND METHODS FOR MODULATING FOXP3 EXPRESSION

#2814

20160122759

2016-05-05

Dosages and methods for delivering lipid formulated nucleic acid molecules

#2815

20160115476

2016-04-28

Compositions and methods for inhibiting expression of the ALAS1 gene

#2816

20160115218

2016-04-28

Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases

#2817

20160108401

2016-04-21

Complement component C5 iRNA compositions and methods of use thereof

#2818

20160108399

2016-04-21

Modulation of HSP47 expression

#2819

20160108398

2016-04-21

Hydrophobically modified antisense oligonucleotides comprising a ketal group

#2820

20160108397

2016-04-21

Targeting microRNAs for the treatment of fibrosis

#2821

20160108395

2016-04-21

CHIMERIC SINGLE-STRANDED ANTISENSE POLYNUCLEOTIDES AND DOUBLE-STRANDED ANTISENSE AGENT

#2822

20160102312

2016-04-14

Compositions and methods for inhibiting expression of the HAMP gene

#2823

20160090599

2016-03-31

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

#2824

20160090598

2016-03-31

Antisense compounds and uses thereof

#2825

20160090596

2016-03-31

Compositions and methods for modulating apolipoprotein (a) expression

#2826

20160090595

2016-03-31

Compositions and methods for modulating apolipoprotein C-III expression

#2827

20160081944

2016-03-24

Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same

#2828

20160076040

2016-03-17

Therapeutic compositions

#2829

20160076034

2016-03-17

RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)

#2830

20160076032

2016-03-17

Compositions and methods

#2831

20160076031

2016-03-17

Phosphorous-linked oligomeric compounds and their use in gene modulation

#2832

20160076030

2016-03-17

Compositions and methods for modulating HBV expression

#2833

20160068846

2016-03-10

Modulation of androgen receptor expression

#2834

20160068845

2016-03-10

Modulation of dystrophia myotonica-protein kinase (DMPK) expression

#2835

20160068842

2016-03-10

miR-29 mimics and uses thereof

#2836

20160068840

2016-03-10

RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF

#2837

20160067355

2016-03-10

Composition for delivery of genetic material

#2838

20160060626

2016-03-03

MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION

#2839

20160060625

2016-03-03

MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION

#2840

20160053269

2016-02-25

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

#2841

20160053262

2016-02-25

Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means

#2842

20160053256

2016-02-25

COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN

#2843

20160053254

2016-02-25

Treatment of genetic disorders associated with DNA repeat instability

#2844

20160046945

2016-02-18

Modulation of hepatitis B virus (HBV) expression

#2845

20160046944

2016-02-18

Aptamer to IL-17 and use thereof

#2846

20160046942

2016-02-18

Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG

#2847

20160046941

2016-02-18

Targeting microRNAs for the treatment of liver cancer

#2848

20160046940

2016-02-18

Targeting microRNAs for metabolic disorders

#2849

20160046931

2016-02-18

Methods for enhancing utrophin production via inhibition of microRNA

#2850

20160032289

2016-02-04

Oral delivery of therapeutically effective LNA oligonucleotides

#2851

20160032286

2016-02-04

Inhibitors of MYH7B and uses thereof

#2852

20160032285

2016-02-04

Compositions and methods for modulating Tau expression

#2853

20160024508

2016-01-28

Method for identifying biologically active oligonucleotides capable of modulating the immune system

#2854

20160024506

2016-01-28

Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT

#2855

20160024505

2016-01-28

Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene

#2856

20160024499

2016-01-28

Compositions and methods for inhibition of expression of protein C (PROC) genes

#2857

20160024496

2016-01-28

Methods for monitoring C9ORF72 expression

#2858

20160024495

2016-01-28

LNA antisense oligonucleotides for the modulation of Myc expression

#2859

20160024494

2016-01-28

COMPOSITIONS AND METHODS FOR ENHANCED SENSITIVITY AND SPECIFICITY OF NUCLEIC ACID SYNTHESIS

#2860

20160017337

2016-01-21

Compositions and Methods for Inhibiting Expression of Eg5 Gene

#2861

20160017335

2016-01-21

PCSK9 iRNA compositions and methods of use thereof

#2862

20160017330

2016-01-21

Serpinc1 iRNA compositions and methods of use thereof

#2863

20160017329

2016-01-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#2864

20160017328

2016-01-21

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION

#2865

20160017322

2016-01-21

Reducing intron retention

#2866

20160010093

2016-01-14

Oligomers and oligomer conjugates

#2867

20160010092

2016-01-14

Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP

#2868

20160010091

2016-01-14

Locked nucleic acid inhibitor of miR-145 and uses thereof

#2869

20160010090

2016-01-14

Bridged bicyclic nucleosides

#2870

20160010089

2016-01-14

Organic compositions to treat EPAS1-related diseases

#2871

20160002640

2016-01-07

Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1

#2872

20160002632

2016-01-07

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#2873

20160002631

2016-01-07

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#2874

20160002628

2016-01-07

METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS

#2875

20160002627

2016-01-07

Compositions and methods for modulation of SMN2 splicing in a subject

#2876

20160002625

2016-01-07

Cancer treatment

#2877

20150376625

2015-12-31

Selective antisense compounds and uses thereof

#2878

20150376623

2015-12-31

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

#2879

20150376616

2015-12-31

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#2880

20150376615

2015-12-31

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#2881

20150376614

2015-12-31

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

#2882

20150376612

2015-12-31

CCCTC-Binding Factor (CTCF) RNA Interactome

#2883

20150368644

2015-12-24

TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1

#2884

20150368642

2015-12-24

LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES

#2885

20150361433

2015-12-17

Inhibitors of miRNAs 221 and 222 for anti-tumor activity in multiple myeloma

#2886

20150361427

2015-12-17

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

#2887

20150353931

2015-12-10

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#2888

20150353930

2015-12-10

Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta

#2889

20150344879

2015-12-03

Compounds and methods for modulating gene expression

#2890

20150337318

2015-11-26

RNA TARGETED TO C-MET

#2891

20150337317

2015-11-26

dsRNA For Treating Viral Infection

#2892

20150337312

2015-11-26

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#2893

20150337307

2015-11-26

Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene

#2894

20150337305

2015-11-26

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#2895

20150337304

2015-11-26

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#2896

20150337303

2015-11-26

Methods and compositions for modulating apolipoprotein (a) expression

#2897

20150329866

2015-11-19

Methods of treating ischemia-reperfusion injury with siRNAs

#2898

20150329864

2015-11-19

DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS

#2899

20150329859

2015-11-19

SELECTIVE REDUCTION OF ALLELIC VARIANTS

#2900

20150322436

2015-11-12

Oligomeric compounds and compositions for the use in modulation of micrornas

#2901

20150322429

2015-11-12

SNPs OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION

#2902

20150322428

2015-11-12

COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS

#2903

20150315597

2015-11-05

Synthetic Nucleic Acids for Polymerization Reactions

#2904

20150315596

2015-11-05

Antisense modulation of PTP1B expression

#2905

20150315594

2015-11-05

Compositions and methods for modulating angiopoietin-like 3 expression

#2906

20150315591

2015-11-05

NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF

#2907

20150315588

2015-11-05

Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers

#2908

20150315587

2015-11-05

Multimeric oligonucleotides compounds having cleavable linkers

#2909

20150315586

2015-11-05

METHODS OF DELIVERING MULTIPLE TARGETING OLIGONUCLEOTIDES TO A CELL USING NON-NUCLEOTIDE BASED CLEAVABLE LINKERS

#2910

20150315585

2015-11-05

Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers

#2911

20150315582

2015-11-05

Deep intronic target for splicing correction on spinal muscular atrophy gene

#2912

20150315580

2015-11-05

COMPOUNDS AND METHODS FOR IMPROVING CELLULAR UPTAKE OF OLIGOMERIC COMPOUNDS

#2913

20150315579

2015-11-05

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION

#2914

20150315575

2015-11-05

Compositions and methods for selective delivery of oligonucleotide molecules to cell types

#2915

20150307877

2015-10-29

Compositions and their uses directed to huntingtin

#2916

20150299710

2015-10-22

Inhibitory oligonucleotide and use thereof

#2917

20150299704

2015-10-22

Methods for treatment of alport syndrome

#2918

20150299703

2015-10-22

In vivo gene silencing by chemically modified and stable siRNA

#2919

20150299701

2015-10-22

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

#2920

20150299699

2015-10-22

MICROMIRs

#2921

20150299695

2015-10-22

Multimeric oligonucleotides compounds

#2922

20150297629

2015-10-22

MODULATION OF RENIN-ANGIOTENSIN SYSTEM (RAS) RELATED DISEASES BY ANGIOTENSINOGEN

#2923

20150291960

2015-10-15

MODULATION OF CD40 EXPRESSION

#2924

20150291956

2015-10-15

RNA TARGETED TO BETA CATENIN

#2925

20150291955

2015-10-15

Antisense compounds targeting genes associated with fibronectin

#2926

20150290289

2015-10-15

Method of promoting wound healing

#2927

20150284726

2015-10-08

RNAi inhibition of alpha-ENaC expression

#2928

20150284725

2015-10-08

Methods of treating kennedy's disease

#2929

20150284708

2015-10-08

Oligonucleotide complex compositions and methods of use as gene alteration tools

#2930

20150275283

2015-10-01

Modified cytosine polynucleotide oligomers and methods

#2931

20150275218

2015-10-01

Organic compositions to treat beta-ENaC-related diseases

#2932

20150275217

2015-10-01

RIG-I ligands and methods for producing them

#2933

20150275216

2015-10-01

Methods and compositions for inhibition of immune responses and autoimmunity

#2934

20150275212

2015-10-01

Oligonucleotide conjugates

#2935

20150275205

2015-10-01

Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome

#2936

20150267204

2015-09-24

Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

#2937

20150267200

2015-09-24

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

#2938

20150267197

2015-09-24

Methods for modulating C9ORF72 expression

#2939

20150267195

2015-09-24

Oligomeric compounds comprising bicyclic nucleosides and uses thereof

#2940

20150259685

2015-09-17

Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

#2941

20150259680

2015-09-17

Nucleic acid functionalized nonoparticles for therapeutic applications

#2942

20150259679

2015-09-17

Compositions for modulating C9ORF72 expression

#2943

20150259675

2015-09-17

Short interfering ribonucleic acid (siRNA) for oral administration

#2944

20150252371

2015-09-10

Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease

#2945

20150252367

2015-09-10

Modulation of transthyretin expression

#2946

20150252364

2015-09-10

Compositions and methods for modulating SMN gene family expression

#2947

20150247146

2015-09-03

Piggy back delivery of nucleic acids into organisms

#2948

20150247143

2015-09-03

Complement component C5 iRNA compositions and methods of use thereof

#2949

20150247142

2015-09-03

ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY

#2950

20150232850

2015-08-20

Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)

#2951

20150232848

2015-08-20

Methods targeting miR-128 for regulating cholesterol/lipid metabolism

#2952

20150232842

2015-08-20

Treatment of fibrotic conditions

#2953

20150232841

2015-08-20

Methods for use in modulating miR-122A

#2954

20150232840

2015-08-20

Methods and compositions for treating neurological disease

#2955

20150232836

2015-08-20

COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION

#2956

20150225725

2015-08-13

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

#2957

20150225724

2015-08-13

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

#2958

20150225717

2015-08-13

Selective reactivation of genes on the inactive X chromosome

#2959

20150218561

2015-08-06

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#2960

20150218559

2015-08-06

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

#2961

20150211011

2015-07-30

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#2962

20150211010

2015-07-30

Restoration of the CFTR function by splicing modulation

#2963

20150211006

2015-07-30

Chiral control

#2964

20150203850

2015-07-23

Methods of treatment using TLR7 and/or TLR9 inhibitors

#2965

20150203849

2015-07-23

Oligonucleotide comprising an inosine for treating DMD

#2966

20150197753

2015-07-16

Method for Generating Aptamers with Improved Off-Rates

#2967

20150197750

2015-07-16

Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP

#2968

20150191733

2015-07-09

Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same

#2969

20150191723

2015-07-09

Modulation of UBE3A-ATS expression

#2970

20150191722

2015-07-09

COMPOSITIONS AND METHODS FOR MODULATING APOA1 AND ABCA1 EXPRESSION

#2971

20150191523

2015-07-09

Toll-like receptors

#2972

20150184164

2015-07-02

ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION

#2973

20150184157

2015-07-02

MODULATION OF TRANSTHYRETIN EXPRESSION

#2974

20150184156

2015-07-02

MODULATION OF APOLIPOPROTEIN (a) EXPRESSION

#2975

20150184155

2015-07-02

METHODS FOR PREVENTING AND TREATING CHRONIC KIDNEY DISEASE (CKD)

#2976

20150176007

2015-06-25

Compositions and methods for modulating HBV expression

#2977

20150176005

2015-06-25

Modulation of enhancer RNA mediated gene expression

#2978

20150167008

2015-06-18

Antisense modulation of superoxide dismutase 1, soluble expression

#2979

20150167007

2015-06-18

TREATMENT OF SIALIDASE 4 (NEU4) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NEU4

#2980

20150167006

2015-06-18

Oligomeric compounds and methods

#2981

20150166999

2015-06-18

Chiral nucleic acid adjuvant

#2982

20150166996

2015-06-18

Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene

#2983

20150166995

2015-06-18

Antisense nucleic acids

#2984

20150166994

2015-06-18

Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG

#2985

20150166465

2015-06-18

Lipid formulations

#2986

20150159163

2015-06-11

Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

#2987

20150159162

2015-06-11

Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

#2988

20150159155

2015-06-11

Modulation of huntingtin expression

#2989

20150152426

2015-06-04

Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4

#2990

20150152425

2015-06-04

Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA

#2991

20150152424

2015-06-04

Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1

#2992

20150152420

2015-06-04

Compounds and methods for altering RSV replication rate

#2993

20150152419

2015-06-04

Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3

#2994

20150152417

2015-06-04

Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity

#2995

20150152414

2015-06-04

Chemical modification of short small hairpin RNAs for inhibition of gene expression

#2996

20150152411

2015-06-04

METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION

#2997

20150152410

2015-06-04

COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION

#2998

20150148404

2015-05-28

RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

#2999

20150141493

2015-05-21

Antisense modulation of GCCR expression

#3000

20150141489

2015-05-21

Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway